Abstract
SummaryOver the past decades, asymmetric catalysis has been intensely investigated as a powerful tool for the preparation of numerous chiral biologically active compounds. However, developing general and practical strategies for preparation of both enantiomers of a chiral molecule via asymmetric catalysis is still a challenge, particularly when the two enantiomers of a chiral catalyst are not easily prepared from natural chiral sources. Inspired by the biologic system, we report herein an unprecedented catalytic enantiodivergent Michael addition of pyridazinones to enones by subtle adjustment of achiral amino moiety of dipeptide phosphine catalysts. These two dipeptide phosphine catalysts, P5 and P8, could deliver both enantiomers of a series of N2-alkylpyridazinones in good yields (up to 99%) with high enantioselectivities (up to 99% ee) via the catalyst-controlled enantiodivergent addition of pyridazinones to enones.
Highlights
The development of efficient methods to synthesize both enantiomers of a chiral molecule is of great significance, because drug candidates and their isomers may have distinct therapeutic properties or adverse effects (Wermuth, 2008; Jozwiak et al, 2012)
Inspired by the biologic system, we report an unprecedented catalytic enantiodivergent Michael addition of pyridazinones to enones by subtle adjustment of achiral amino moiety of dipeptide phosphine catalysts
Sickle cell anemia is an autosomal recessive genetic disease, caused by a single-base mutation in the beta gene of globin causing glutamate mutated to proline. This sickling leads to the RBC membrane damage and increases the likelihood of rupture and anemia (Gyang et al, 2011). Inspired by this intriguing biological process, we hypothesized that some small structural modifications in conformationally flexible chiral organocatalysts without changing any stereocenter might allow to obtain both stereoisomers in the individual form in asymmetric catalysis as well
Summary
The development of efficient methods to synthesize both enantiomers of a chiral molecule is of great significance, because drug candidates and their isomers may have distinct therapeutic properties or adverse effects (Wermuth, 2008; Jozwiak et al, 2012). Sickle cell anemia is an autosomal recessive genetic disease, caused by a single-base mutation in the beta gene of globin causing glutamate mutated to proline. This sickling leads to the RBC membrane damage and increases the likelihood of rupture and anemia (Gyang et al, 2011). Inspired by this intriguing biological process, we hypothesized that some small structural modifications in conformationally flexible chiral organocatalysts without changing any stereocenter might allow to obtain both stereoisomers in the individual form in asymmetric catalysis as well
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
